China Medical Device Regulatory Hierarchy: Law, Regulations, Rules, Documents, Guidelines

1. Key takeaways

The Chinese framework is a five-tier pyramid: authority falls downwards, volume rises.

• No device-specific law. Order No. 739, promulgated 9 February 2021 and effective 1 June 2021, is the parent basis for all rules and notices.
• Product and enterprise groups. Orders No. 47 and No. 48 govern device and IVD registration; Orders No. 53 and No. 54 govern production and distribution.
• Rules are stable, notices are not. Order No. 47 has applied since 1 October 2021, while 2025 alone produced No. 30, No. 46, No. 63 and No. 107.
• Guidance shapes review without binding. It is not a legal basis for approval but is the direct source of review questions and deficiencies.

The GRZAN view. Ignoring tiers produces two opposite errors: treating guidance as law, or treating it as optional and drafting to the wrong standard. Statutes say whether something may be done; guidance says how far it must go.

2. Legal basis

Administrative regulation. Regulations on Supervision and Administration of Medical Devices, State Council Order No. 739, promulgated 9 February 2021, effective 1 June 2021. Article 3 divides supervision between the NMPA and local authorities; Article 5 sets risk management, whole-process control, scientific supervision and co-governance as principles; Article 6 establishes risk classification and gives the NMPA the rules and catalogue; Article 13 makes Class I a filing and Classes II and III registrations, with registrants liable for safety and effectiveness; Article 16 assigns domestic Class II to the province and Class III to the NMPA; Article 23(2) sets 20 working days for class confirmation.

It began as Order No. 276 of 4 January 2000, was revised on 12 February 2014, amended on 4 May 2017 and revised on 21 December 2020. Guobanfa No. 53 of 2024, issued 30 December 2024, adds 24 measures in five areas with goals for 2027 and 2035.

Departmental rules. SAMR Order No. 47, promulgated 26 August 2021, effective 1 October 2021: Article 4 gives the NMPA the national registration system; Article 5 gives the NMPA Center for Medical Device Evaluation technical review of domestic Class III, import Class II and III and trial applications; Article 6 gives provinces domestic Class II review and system inspection; Article 8 sets the filing levels; Article 121 refers IVDs to Order No. 48; Article 124 repeals Order No. 4 of 30 July 2014.

Order No. 48 on IVDs was promulgated 26 August 2021 and effective 1 October 2021. Order No. 53, on production, promulgated 10 March 2022 and effective 1 May 2022, requires licences for Classes II and III and filing for Class I (Article 4) and divides supervision between the NMPA and provinces (Article 5). Order No. 54, on distribution, was promulgated 10 March 2022 and effective 1 May 2022. Former Order No. 6, promulgated 30 July 2014 and effective 1 October 2014, requires Chinese text in instructions and labels (Article 9).

Normative and technical documents. Announcement No. 63 of 2025 covers robots, high-end imaging, artificial intelligence and new biomaterials; No. 30 of 2025 adjusts local production of imported devices; No. 46 of 2025, effective 1 October 2025, governs online sales; No. 107 of 2025, issued 4 November 2025 and effective 1 November 2026, replaces the 2014 practice with 15 chapters and 132 articles and repeals No. 64 of 2014. Submission formats follow No. 121 and No. 122 of 2021, self-testing follows No. 126 of 2021, Notice No. 50 of 2022 sets four inspection outcomes, the trial practice No. 28 of 2022 has nine chapters and 66 articles, and the 2025 exemption catalogue, No. 19 of 2025, covers 1,047 products.

Practical estimate. No consolidated official list of current guidance exists; search the NMPA review center publications by product category before filing.

3. Expert insights

What differs is who bears the consequence. Lower tiers do not punish, they block, which is why they are underestimated.

Four rules cover two products and two enterprise subjects. This explains why a Class III certificate comes from the NMPA under Article 8 of Order No. 47 while the production licence comes from the province under Article 4 of Order No. 53: it is design, not inconsistency. Article 121 keeps IVDs in a parallel regime.

Monitor rules and notices on different clocks. Full review belongs to a rule change, targeted quarterly search to notices. Catalogue documents carry a year suffix, which signals frequent replacement.

Guobanfa No. 53 of 2024 is policy, not a citation. It supports strategy and anticipation of legislation but cannot ground a submission or a dispute; policy lands through amended rules and notices such as Announcement No. 63 of 2025.

Guidance sets the standard within a hard boundary. Review questions, deficiency citations and expectations on data depth trace to guidance, yet a guideline cannot override the law: where it recommends a sample size and a mandatory standard requires another, the standard prevails.

Conflicts resolve in three steps. Higher tier over lower, later over earlier from the same issuer, and specific over general, which is why IVDs follow Order No. 48 and Announcement No. 122 of 2021.

4. Practical recommendations

• Keep a five-tier register. Full review when a rule is replaced, quarterly searches for notices and guidance, immediate replacement of catalogue documents.
• Cite tier and document number. Give the full title, number, date and article, which prove the instrument is current.
• Route all IVDs through Order No. 48; using the Order No. 47 framework is a common error.
• Search guidance by category and map each applicable guideline against the file.
• Separate policy from law. Use Guobanfa No. 53 of 2024 and Announcement No. 63 of 2025 for strategy only.
• Treat 1 November 2026 as a hard deadline. Complete the gap analysis and document conversion before the new practice applies.
• Log repeals separately. Order No. 47 repealed Order No. 4 of 2014, No. 107 of 2025 repealed No. 64 of 2014, and Notice No. 50 of 2022 repealed Notice No. 19 of 2020.
• Apply changes across the lifecycle. Marketed products still face standard and catalogue changes, with updates under Article 21 and Article 79 of Order No. 47.

5. Verification checklist

• □ Five-tier register built.
• □ Current Order No. 739 recorded with dates.
• □ Orders No. 47, 48, 53, 54 and former Order No. 6 recorded with dates.
• □ Repeals logged: Order No. 4 of 2014, No. 64 of 2014, Notice No. 19 of 2020.
• □ IVD products routed through Order No. 48 and Announcement No. 122.
• □ Category-specific guidance list compiled and compared.
• □ Citations carry document number and publication date.
• □ Policy and legal documents kept separate.
• □ Conflict order internalised: higher tier, later date, specific rule.
• □ Quarterly targeted search running.
• □ 1 November 2026 conversion milestone scheduled.
• □ Change mechanism for marketed product documents established.
• □ Full and targeted review triggers written into the quality system.

Verified as at 29 October 2026 against NMPA, SAMR and State Council publications; practical estimates have no legal effect.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Chinese market. Our team manages National Medical Products Administration (NMPA) registrations, coordinates typetesting at qualified testing institutes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com